Literature DB >> 16382193

Naloxone precipitates nicotine abstinence syndrome and attenuates nicotine-induced antinociception in mice.

Grazyna Biała1, Barbara Budzyńska, Marta Kruk.   

Abstract

The present study focused on the evaluation of a role of opioid system in nicotine-induced antinociception and physical dependence in mice. The results indicate that nicotine (3 mg/kg) produced a significant antinociception in the hot plate test. Additionally, the opioid receptor antagonist naloxone (0.5 and 1 mg/kg), dose-dependently attenuated this effect. Our second experimental protocol consisted in intermittent administration of nicotine (2.5 mg/kg, s.c.) four times daily for 7 days. In order to precipitate nicotine abstinence, mice were given one injection of mecamylamine (3 mg/kg) or naloxone (1 mg/kg) one hour after the last nicotine injection on the test day (day 8) in the morning. Interestingly, our findings revealed that both drugs precipitated somatic withdrawal signs in mice, with a slight difference in their influences on the intensity of several signs. These data support the hypothesis that similar opioid-cholinergic interactions are involved in nicotine-induced antinociception and nicotine withdrawal syndrome.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16382193

Source DB:  PubMed          Journal:  Pharmacol Rep        ISSN: 1734-1140            Impact factor:   3.024


  18 in total

1.  Attenuated beta endorphin response to acute stress is associated with smoking relapse.

Authors:  Darcy Shaw; Mustafa al'Absi
Journal:  Pharmacol Biochem Behav       Date:  2008-04-03       Impact factor: 3.533

2.  Effects of smoking cessation on pain in older adults.

Authors:  Yu Shi; W Michael Hooten; David O Warner
Journal:  Nicotine Tob Res       Date:  2011-05-12       Impact factor: 4.244

Review 3.  Achieving Smoking Cessation Among Persons with Opioid Use Disorder.

Authors:  Cynthia Vlad; Julia H Arnsten; Shadi Nahvi
Journal:  CNS Drugs       Date:  2020-04       Impact factor: 5.749

4.  Effects of varenicline and mecamylamine on the acquisition, expression, and reinstatement of nicotine-conditioned place preference by drug priming in rats.

Authors:  Grazyna Biala; Natasza Staniak; Barbara Budzynska
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2010-03-10       Impact factor: 3.000

Review 5.  New mechanisms and perspectives in nicotine withdrawal.

Authors:  K J Jackson; P P Muldoon; M De Biasi; M I Damaj
Journal:  Neuropharmacology       Date:  2014-11-26       Impact factor: 5.250

Review 6.  Neurobiological mechanisms involved in nicotine dependence and reward: participation of the endogenous opioid system.

Authors:  Fernando Berrendero; Patricia Robledo; José Manuel Trigo; Elena Martín-García; Rafael Maldonado
Journal:  Neurosci Biobehav Rev       Date:  2010-02-16       Impact factor: 8.989

7.  Attenuation by baclofen of nicotine rewarding properties and nicotine withdrawal manifestations.

Authors:  Andrés P Varani; Ester Aso; Lirane Machado Moutinho; Rafael Maldonado; Graciela N Balerio
Journal:  Psychopharmacology (Berl)       Date:  2014-02-20       Impact factor: 4.530

8.  Adolescent rats are resistant to adaptations in excitatory and inhibitory mechanisms that modulate mesolimbic dopamine during nicotine withdrawal.

Authors:  Luis A Natividad; Matthew W Buczynski; Loren H Parsons; Oscar V Torres; Laura E O'Dell
Journal:  J Neurochem       Date:  2012-10-01       Impact factor: 5.372

Review 9.  Endogenous opioid system: a promising target for future smoking cessation medications.

Authors:  Haval Norman; Manoranjan S D'Souza
Journal:  Psychopharmacology (Berl)       Date:  2017-03-11       Impact factor: 4.530

10.  Nicotine anxiogenic and rewarding effects are decreased in mice lacking beta-endorphin.

Authors:  José M Trigo; Andreas Zimmer; Rafael Maldonado
Journal:  Neuropharmacology       Date:  2009-04-17       Impact factor: 5.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.